Related Experiment Video
Updated: May 17, 2026
08:43
Chronic Ovine Model of Right Ventricular Failure and Functional Tricuspid Regurgitation
Published on: March 17, 2023
Per3 VNTR polymorphism and chronic heart failure
Jolana Lipkova1, Julie Anna Bienertova-Vasku, Lenka Spinarova
1Institute of Pathological Physiology, Faculty of Medicine, Masaryk University Brno, Czech Republic.
Summary
The Period3 (Per3) variable number tandem repeat (VNTR) polymorphism does not appear to be a significant risk factor for developing chronic heart failure (CHF). This genetic variation also did not influence the severity of CHF in the studied Caucasian population.
Area of Science:
- Genetics
- Cardiology
- Molecular Biology
Background:
- Chronic heart failure (CHF) is a complex condition with various contributing factors.
- Genetic polymorphisms are increasingly investigated for their role in disease susceptibility and progression.
Purpose of the Study:
- To examine the association between the Period3 (Per3) gene variable number tandem repeat (VNTR) polymorphism and the risk of developing chronic heart failure (CHF).
- To determine if Per3 VNTR polymorphism influences the severity of CHF in affected individuals.
Main Methods:
- Genotyping of Per3 VNTR polymorphism in 372 Caucasian patients with CHF and 332 healthy controls using allele-specific PCR.
- Statistical analysis including genotype and allele frequency comparisons, and multivariate regression modeling.
Main Results:
- No significant differences in Per3 VNTR genotype or allele frequencies were observed between CHF patients and healthy controls.
- No significant associations were found between Per3 VNTR polymorphism and CHF etiology (dilated cardiomyopathy vs. ischemic heart disease).
- Multivariate regression analysis indicated no predictive role of Per3 VNTR polymorphism for ejection fraction, NYHA class, hyperlipidemia, or type II diabetes risk.
Conclusions:
- The Per3 VNTR polymorphism is not identified as a major genetic risk factor for chronic heart failure in the studied population.
- This genetic variation does not appear to modulate the clinical severity of chronic heart failure.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:20Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...